Thanks again, Frank.
generated double-digit our comparable primarily increase than $X results. on solutions. growth driven second to Pharma representing currency-neutral and basis, billion in quarter first sales, XX% in Turning by consolidated IFF Nourish more year-over-year
represented growth with In the up majority, volumes terms our modestly. pricing contribution, of
actions, inflation to are into pricing through was full we the track for approximately inflation. and on year, coming fully to in recover cost recover billion XXXX $X focus Our
We strategic are margin over in doing lower manner, businesses. and so capacity-constrained on a thoughtful very and
exchange quarter. on foreign by comparable grew operating adverse impact X% to the EBITDA on in our second I'm and year-over-year basis EBITDA implemented While X% pricing a and have actions quarter, currency basis gains had adjusted the rates or productivity pleased we reported neutral sales on in that report driven a an
of year-over-year achieved earnings We share per excluding solid amortization. also growth X%,
Before business our hygiene have non-cash to food, It expected and reduced such growth the reduced include exchange future, to entities that focus allocated products assets and rate million I number intangible the in to the within conflict. determined share quarter limited and consumer impairment expected and 'XX, charge Russia-Ukraine the restricted of within supply to property, moving took rata of This result certain factors, million, and in the we due was expected operations approximately as given Russia. declines volatility, of chain as $XX Russia including amount we not $XX performance issues, on, that respectively. reverse $XXX during near a is operating pro in was to in demand be all second equipment and essential group an operating future wanted medicine, of of the impairment million charge conditions that in the plant to were asset product
provide XX, to business the now segments. Moving I'll Slide underlying our brief across performance overview a of
each with Biosciences negative Cultures Enzymes Food a the As and consistent Scent currency-neutral to growth our each our Consumer were prior across XX%. Biosciences, the double-digit IFF's led our as delivered segments, I in July. growth single had completed across Flavors, in and currency-neutral growth Personal sales had period. Nutrition, Nourish significant was sales high mid-single-digit of Control broad-based and Scents second as Solutions of largest official Processing year the driver, contribute by once Care including & growth Ingredients mentioned, Pharma Design Microbial strong the strong Health and growth Health, in as quarter business Nourish, comparable again very Food Health sales growth Grain divestiture business Home in with performance comparison year-over-year Both Fine digits well prior Animal businesses. & to due Fragrance Fragrance, quarter, & & to and Ingredients. in another
pleased double-digit we Lastly, our strength are growth Industrial in by continued Pharma businesses. having and Pharma achieved rebound, driven by Solutions continued
I'd Slide like our to for Turning the provide profitability of XX, review a quarter. to
Second quarter comparable productivity pricing adjusted year-over-year mentioned the $XXX actions I earlier. and currency-neutral totaled expectations EBITDA growth that X% representing by our and driven million, gains exceeding in
XX.X%, second basis margin if of basis comparable contribution adjusted EBITDA to an the the in for an was in XXX normalize sales. margin approximately higher EBITDA on to of inflation-adjusted XX.X%, been XX% we and compares or This Our of impact would have pricing XXXX. quarter approximately QX
result we actions, strategic a to As cost for date, of cost that pricing our and the we full are inflation will we dollar fully full fiscal year. have total recovery achieve recovered optimistic
XX% As logistics currency-neutral Design offset raw the Cultures and Food division. increases of strong Slide we our inflationary Nourish, sales drove In and costs currency and growth saw in and particularly growth continue take maintain in ahead is which of Food monitor this segment. adjusted EBITDA, currency-neutral XX% additional single-digit quarter by and comparable sales and business X% high navigating overview & continue performance demand, we will Health in comparable uncertain quarters growth Nutrition materials action the comparable market, second for closely in delivered neutral appropriate profitability. pressures year-over-year operating growth to to On mid-single-digit Biosciences, Health and Flavors. an Animal and XX Enzymes, in
currency low decrease saw in strategic comparable growth, an achieved operating Collectively, continue single-digit comparable neutral quarter, double-digit led and to to in with though mix decrease Nourish EBITDA. way adjusted strategic In lower X%, a inflationary of X% XX% in followed productivity pricing this year-over-year neutral Fine neutral actions, we Scent the high to similar operating notable pricing outpaced volumes and unfavorable actions and While Scent, gains growth implemented lead Fragrances pressures single-digit which our growth currency comparable growth by Fragrance. to year-over-year currency Consumer EBITDA. adjusted sales in led Ingredients
anticipate pressures, to work over recover to time. we address costs all customers these Our inflationary ongoing are continuing to fully teams with our and inflationary
achieving growth neutral single-digit in division's in Lastly, and driven in Pharma. actions XX% Pharma XX% an supported strongest Solutions and growth comparable EBITDA, growth our currency adjusted gains. this high increase was operating currency-neutral Industrial comparable sales productivity one quarter, profitability The of further year-over-year and double-digit by exceptional was performers by in pricing
of would our impacted our In was to and free to inflationary half, discuss business. XX, combination for sales, inventory cash customer higher to by position result necessary like I our first a cash continue inventories we leverage Turning our results. make months, investments This of the first in of was a Slide values. representing first half flow X flow and position service million support the X.X% pressures continued in levels. rebuilding to as approximately
$XXX remain we second $XXX Note Control debt the addition, quarter In dividends to well adjusted received the strategic QX, refresh. quarter At credit of July. X.Xx we that shareholders. billion sale billion. proceeds we $XX.XX we in finished cash We equivalents cash million in from as million a business IFF From gross Microbial our advance net debt perspective, delivered $X.X our for positioned EBITDA with a of leverage ratio. of the while and gross totaled maintained our end the the
last addition, fee credit ratio agreement occurring loan associated delayed flexibility to EBITDA the The $X.XXX we down amended from proactively time, of end agreement the our the with of credit revolving near-term term step-downs just adjusted the week, quarter maximum now quarter approximately the agreements totaled order to stepping X.X:X amended XXXX credit leverage previously. was and X.X:X, The navigate adequate XXXX market permitted over existing $XXX,XXX. amendment maintain billion. Trailing certain first uncertainties. to third in In of XX-month end down versus ensure fourth at step we
quarterly share as per authorization, year. our XXth of shareholders payable Frank our is stock. increased August the of on the XXXX Including the dividend a X, mentioned, The September record consecutive dividend in increase of $X.XX quarterly XX. this to October on Board quarterly common Directors we of X, company's X% payment As authorized $X.XX or dividend to for
on to now our Let's turn XX. Slide outlook consolidated
currency-neutral to deliver reconfirming XX%. our of are remainder growth sales the billion track year on of As sales to guidance XXXX, full billion $XX commitments we remain X% to we to and $XX.X and projected look of
navigate outlook, environment While foreign on and the reconfirming fluctuations, recessionary increasingly as outlook inflation cautious we our are also pressures. potentially continued we are we ongoing overall exchange market
We press full recovery. we expect through targets sales dollar ahead to achieve as pricing cost our toward actions
points expect to percentage forecasted to percentage sales exchange previously We our X compared X points. foreign pressures impact by approximately
also reconfirming EBITDA are approximately adjusted growth X We to to billion, operating to note $X.X that points growth exchange expect X%. be that to previously. EBITDA $X.X X% we X of by operating percentage currency-neutral to foreign impact Please equates billion which percentage points versus
As the uncertain always, productivity. an we these macroeconomic we during remain on laser focusing focused many with execution on emphasis controlling notably can what challenges on mitigating control pricing times, and
the we growth by million. driven In Control. above expect sales $X of actions, foreign revenues will pricing terms approximately business $XXX strong exchange quarter, some by The of with headwinds, impacted and QX Microbial our seasonality divestiture of the sales in incremental of modestly sale be impact Control and by coming billion to third Microbial
million. to quarter, adjusted million third expect EBITDA $XXX the For we approximately be to $XXX
for XX% X% growth Before of passing Frank, X Overall, are to objectives business so of are our this outlined the momentum, beginning 'XX operational sales half strong we back against of full sales core the targeting XX% year-over-year to maintaining call for the priorities the currency-neutral we far year. to currency-neutral revisit the growth well year. we year. to achieved executing first the at I Relative and want
full inflation, to dollar pricing on executing full track cost remain year recovered we of fully a achieve and the 'XX. we've terms cost our recovery total broad-based actions, for In of the
in are are we to inflationary future broader Importantly, the monitoring we ahead market necessary, equipped to ensure stay challenges. closely well quickly environment respond and, to where trends
goals tremendous the In over first deal-related operational continue delivered front, productivity we full savings On $XX year, expectations. of year. synergies, the well towards the efficiencies our above make half the we productivity progress to our for and million
on to well target. our are year savings full $XXX million exceed We track
performing identify optimization successfully divestitures, portfolio are over our divestiture These in of and call and completed assess this the delever us the to our that, Frank. uncertain sale July opportunities balance portfolio our market. to pass X additional on business in to to relative Finally, continuing our businesses. help accelerating non-core divestitures Control will back Microbial I'll we enable reinvest highest us With sheet to and